Allogeneic transplantation for advanced leukemia: Improved short-term outcome with blood stem cell grafts and tacrolimus

Transplantation

Volumn 62, Issue 12, 1996, Pages 1806-1810

  Przepiorka, Donna ^a,b   Ippoliti, Cindy ^a   Khouri, Issa ^a   Anderlini, Paolo ^a   Mehra, Rakesh ^a   Giralt, Sergio ^a   Gajewski, James ^a   Fritsche, Herbert ^a   Deisseroth, Albert B ^a   Cleary, Karen ^a   Champlin, Richard ^a   Van Besien, Koen ^a   Andersson, Borje ^a   Korbling, Martin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; FEMALE; GRAFT SURVIVAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHILD; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; MIDDLE AGED; SURVIVAL RATE; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 8044231318     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199612270-00022     Document Type: Conference Paper

References (23)

1. Körbling M, Przepiorka D, Huh YO, et al. Successful allogeneic blood stem cell transplantation for refractory acute myelogenous leukemia: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659.
2. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655.
3. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666.
4. Przepiorka D, Anderlini P, Ippoliti C, et al. Allogeneic blood stem cell transplantation: reduction in early treatment-related morbidity and mortality for patients with advanced hematologic malignancies. Bone Marrow Transplant (in press).
5. Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE. FK506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery 1991; 110: 357.
6. Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 1991; 52: 590.
7. Storb R, Raff RF, Appelbaum FR, et al. FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation 1993; 56: 800.
8. Nash RA, Etzioni R, Storb R, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746.
9. Fay JW, Wingard JR, Antin JH, et al. FK506 monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996; 87: 3514.
10. Przepiorka D, Ippoliti C, Giralt S, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 1994; 14: 449.
11. Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity, laboratory effects and analysis of charges for filgrastim mobilization and blood stem cell apheresis from normal donors. Transfusion 1996; 36: 590.
12. Snover DC. Biopsy interpretation in bone marrow transplantation. In Rosen PP, Fechner RE, eds. Pathology annual: II. Hartford, CT: Appleton & Lange, 1989; 63.
13. Przepiorka D, Weisdorf D, Martin P, et al. Meeting Report. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825.
14. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562.
15. Powles R, Smith C, Milan S, et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind placebo-controlled trial. Lancet 1990; 336: 1417.
16. Schriber JR, Chao NJ, Long GD, et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84: 1680.
17. Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949.
18. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225.
19. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
20. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Eng J Med 1994; 331: 1110.
21. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729.
22. Glass B, Zeis M, Uharek L, et al. A murine model for allogeneic peripheral stem cell transplantation in investigation of engraftment and GVL activity. Bone Marrow Transplant 1996; 17(suppl 1): S63.
23. Anderlini P, Przepiorka D, Khouri I, et al. Chronic graft-vs-host disease after allogeneic marrow or blood stem cell transplantation. Blood 1995; 86(suppl 1): 109a.